Automated Drug Discovery Workflows to Identify the Best Producing Clones with Highest Productivity
Last updated: August 2023
Overview
Antibodies are the ideal therapeutic biomolecule due to their ability to bind to a variety of targets with high affinity and specificity. Innovations in hybridoma and phage display technologies have allowed drug developers to exploit the natural diversity in antibodies, leading to the wide use of monoclonal antibodies (mAbs) in treating cancers, chronic inflammation, and infectious diseases. Whilst single B-cell screening has significantly evolved and is the main source for obtaining antigen-specific mAb sequences, hybridoma screening using semi-solid media still represents an important technology.
This technical note focuses on both methods within the antibody discovery workflow and the role CellCelector can play.
- Document type: Technical Note
- Page count: 8
- Read time: 6 minutes
Key Takeaways
- How target-specific secreting cells can be selected from thousands of potential candidates before further downstream analysis
- The use of Nanowell technology to assess and verify high numbers of clones before transferring the top producers
- The steps of the single B-Cell screening process using the CellCelector platform
Figure 1. Antibody Discovery Workflow
